Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation via Distinct Structural Degrons
There is a growing interest in using targeted protein degradation as a therapeutic modality in view of its potential to expand the druggable proteome. One avenue to using this modality is via molecular glue based Cereblon E3 Ligase Modulating Drug compounds. Here, we report the identification of the transcription factor ZBTB16 as a Cereblon neosubstrate. We also report two new Cereblon modulators, CC-3060 and CC-647, that promote ZBTB16 degradation. Unexpectedly, CC-3060 and CC-647 target ZBTB16 for degradation by primarily engaging distinct structural degrons on different zinc finger domains. The reciprocal fusion proteins, ZBTB16-RARα and RARα-ZBTB16, which cause a rare acute promyelocytic leukemia, contain these same structural degrons and can be targeted for proteasomal degradation with Cereblon modulator treatment. Thus, a targeted protein degradation approach via Cereblon modulators may represent a novel therapeutic strategy in acute promyelocytic leukemia where ZBTB16/RARA rearrangements are critical disease drivers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
ACS chemical biology - 15(2020), 12 vom: 18. Dez., Seite 3149-3158 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matyskiela, Mary E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.07.2021 Date Revised 07.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acschembio.0c00674 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317737015 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317737015 | ||
| 003 | DE-627 | ||
| 005 | 20231225163908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acschembio.0c00674 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1059.xml |
| 035 | |a (DE-627)NLM317737015 | ||
| 035 | |a (NLM)33206504 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matyskiela, Mary E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation via Distinct Structural Degrons |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.07.2021 | ||
| 500 | |a Date Revised 07.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a There is a growing interest in using targeted protein degradation as a therapeutic modality in view of its potential to expand the druggable proteome. One avenue to using this modality is via molecular glue based Cereblon E3 Ligase Modulating Drug compounds. Here, we report the identification of the transcription factor ZBTB16 as a Cereblon neosubstrate. We also report two new Cereblon modulators, CC-3060 and CC-647, that promote ZBTB16 degradation. Unexpectedly, CC-3060 and CC-647 target ZBTB16 for degradation by primarily engaging distinct structural degrons on different zinc finger domains. The reciprocal fusion proteins, ZBTB16-RARα and RARα-ZBTB16, which cause a rare acute promyelocytic leukemia, contain these same structural degrons and can be targeted for proteasomal degradation with Cereblon modulator treatment. Thus, a targeted protein degradation approach via Cereblon modulators may represent a novel therapeutic strategy in acute promyelocytic leukemia where ZBTB16/RARA rearrangements are critical disease drivers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adaptor Proteins, Signal Transducing |2 NLM | |
| 650 | 7 | |a CRBN protein, human |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
| 650 | 7 | |a Promyelocytic Leukemia Zinc Finger Protein |2 NLM | |
| 650 | 7 | |a Retinoic Acid Receptor alpha |2 NLM | |
| 650 | 7 | |a ZBTB16 protein, human |2 NLM | |
| 650 | 7 | |a 147855-37-6 |2 NLM | |
| 650 | 7 | |a Ubiquitin-Protein Ligases |2 NLM | |
| 650 | 7 | |a EC 2.3.2.27 |2 NLM | |
| 700 | 1 | |a Zhu, Jinyi |e verfasserin |4 aut | |
| 700 | 1 | |a Baughman, Joshua M |e verfasserin |4 aut | |
| 700 | 1 | |a Clayton, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Slade, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Hon Kit |e verfasserin |4 aut | |
| 700 | 1 | |a Danga, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xinde |e verfasserin |4 aut | |
| 700 | 1 | |a Labow, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a LeBrun, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Chamberlain, Philip P |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Joel W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS chemical biology |d 2006 |g 15(2020), 12 vom: 18. Dez., Seite 3149-3158 |w (DE-627)NLM167137344 |x 1554-8937 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2020 |g number:12 |g day:18 |g month:12 |g pages:3149-3158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acschembio.0c00674 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2020 |e 12 |b 18 |c 12 |h 3149-3158 | ||